Veru Stock News

State Street Corp raised its position in shares of Veru Inc. (NASDAQ:VERU) by 19.6% in the second quarter, according to its most recent filing with the SEC. The firm owned 1,042,692 shares of the companys stock after purchasing an additional 170,617 shares during the quarter. State Street Corp owned approximately 1.31% of Veru worth $8,415,000 []

Veru Inc. (VERU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Veru Inc. (VERU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Veru Inc. is a rare thing in biotech - a profitable business carrying out 3 pivotal trials for drugs in development targeting oncology and COVID.

Virtu Financial LLC trimmed its position in shares of Veru Inc. (NASDAQ:VERU) by 67.9% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 27,325 shares of the companys stock after selling 57,919 shares during the quarter. Virtu Financial LLCs []

Analysts expect Veru Inc. (NASDAQ:VERU) to report ($0.08) earnings per share (EPS) for the current quarter, according to Zacks. Four analysts have issued estimates for Verus earnings, with the highest EPS estimate coming in at ($0.06) and the lowest estimate coming in at ($0.11). Veru reported earnings per share of ($0.01) in the same quarter []

Overview of Global Contraceptive Devices Market: Contraceptive Devices Market research report has been created with the systematic gathering and evaluation of Market information for Healthcare industry which is presented in a form that explains various facts and figures to the business.

MIAMI, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of breast and prostate cancer,

MIAMI, Nov. 18, 2021 (GLOBE NEWSWIRE) Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of breast and prostate cancer, today announced that it will report financial results for its fiscal 2021 fourth quarter and full year ended September 30, 2021, on Thursday, December 2, The post Veru to Report Fiscal 2021 Fourth-Quarter, Full-Year Financial Results, Host Conference Call on December 2nd appeared first on ForexTV .

-- Veru is a Late-Stage Clinical Development Biopharmaceutical Company Developing Drugs for the Treatment of Breast Cancer, Prostate Cancer, and COVID-19, Large Premium Global Markets

Nuveen Asset Management LLC boosted its position in Veru Inc. (NASDAQ:VERU) by 111.6% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 721,915 shares of the companys stock after acquiring an additional 380,746 shares during the quarter. Nuveen Asset Management LLCs []

MIAMI, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of breast and prostate cancer, to

Brokerages predict that Veru Inc. (NASDAQ:VERU) will post $18.26 million in sales for the current quarter, Zacks reports. Four analysts have issued estimates for Verus earnings. The lowest sales estimate is $17.00 million and the highest is $19.00 million. Veru reported sales of $11.75 million in the same quarter last year, which indicates a positive []

-- Enobosarm is a novel targeted hormone drug to be evaluated in the 3 rd line treatment of androgen receptor positive metastatic breast cancer -- -- A companion diagnostic test will be developed, val

It's a great time to look beyond the big name pharmaceutical stocks and look for great niche players with big futures. The post 7 Top-Rated Pharmaceutical Stocks To Invest in for October appeared firs